SDC3促进肾透明细胞癌并且与不良预后有关

SDC3 is Related to Bad Prognosis and Enhances Renal Clear Cell Carcinoma Progression

肾透明细胞细胞癌(Clear cell renal cell carcinoma,CcR CC)被认为是最常见的肾癌,分子靶向疗法和免疫疗法改善了晚期RCC患者的预后,但是复发、远处转移的进展以及副作用仍然是与这些疗法相关的重要问题.Syndecans是细胞表面分子的4个成员的多功能家族,具有多种生物学作用.Syndecan-3(SDC3)是其中最大的一种,SDC3可以影响多种生理功能,对多种癌症进展也有影响,但其在肾细胞癌组织中的表达及其对肾细胞癌进展和转移的可能作用尚不清楚.根据TCGA数据库和IHC分析,发现在ccR CC组织中SDC3的mR NA和蛋白水平明显升高.SDC3的表达与肾细胞癌患者的预后相关,也与患者的肿瘤大小相关(P=0.023).进一步研究表明,SDC3敲低可抑制ccR CC细胞系的增殖.本研究表明,SDC3的高表达促进了ccR CC细胞的恶性肿瘤,并为开发基于SDC3的新治疗方法提供了思路.

Renal clear cell carcinoma(ccRCC)is considered to be the most common renal cell carcinoma.Molecular targeted therapy and immunotherapy improve the prognosis of patients with advanced RCC,but recurrence,progression of distant metastasis,and side effects are still important issues related to these treatments.Syndecans is a multi-functional family including four cell surface molecule members,which has various biological functions.Syndecan-3(SDC3)is the largest one,which not only can affect a variety of physiological functions but also affect the progression of many cancers.However,its expression in renal cell carcinoma and its possible role in the progression and metastasis of renal cell carcinoma is not clear.According to the TCGA database and IHC analysis,the mRNA and protein levels of SDC3 were significantly increased in ccRCC tissues were found.The expression of SDC3 was associated with the prognosis of patients with renal cell carcinoma and with the tumor size of the patients was found.Further research indicated that SDC3 knockdown inhibits the proliferation of ccRCC cell lines.In summary,our study demonstrated high expression of SDC3 promotes ccRCC cell malignancy and sheds light on developing novel therapeutic approaches based on SDC3.